Mithramycin A, also known as plicamycin, is an aureolic acid-class antitumor antibiotic that functions by binding to GC-rich DNA sequences, thereby inhibiting DNA-dependent RNA synthesis. While historically… Read more
Mithramycin A, also known as plicamycin, is an aureolic acid-class antitumor antibiotic that functions by binding to GC-rich DNA sequences, thereby inhibiting DNA-dependent RNA synthesis. While historically utilized in the treatment of conditions such as testicular cancer, Paget’s disease of bone, and hypercalcemia, its application in contemporary research necessitates stringent analytical oversight. This category encompasses a comprehensive selection of Mithramycin A reference standards, including pharmacopeial and non-pharmacopeial impurities, degradation products, and metabolites. These compounds are vital for pharmaceutical laboratories conducting impurity profiling and method validation, ensuring accurate quantification and regulatory compliance during drug development. Additionally, the availability of stable isotope labelled compounds provides critical internal standards for mass spectrometry-based assays, enabling precise pharmacokinetic analysis and stability testing. Providing these high-quality reference materials supports the rigorous quality control requirements essential for the investigation and continued development of this potent therapeutic agent.